Early Lung Cancer Test Launch into NHS
Jan 24 2021 Read 926 Times
Immunodiagnostics group Oncimmune Holdings plc is to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney Clinical Commissioning Group. Under this commercial contract, Norfolk & Waveney will be evaluating the use of the blood test in a clinical setting. A successful conclusion to this contract, combined with Guidance from NICE, is anticipated to support the adoption of this test into the clinical pathway for the early detection of lung cancer across NHS East of England.
The company is also supplying EarlyCDT Lung blood test into the NHS Lung Health Check Programmes in Wessex and Yorkshire as part of the iDx-LUNG evaluation programme. This will involve collection of blood samples from 15,000 people to be delivered through mobile CT scanning sites across Wessex and Yorkshire. As well as targeting increased survival rates, an aim of the iDx-LUNG programme is to streamline the process of detecting incident lung cancers in the community and so reduce the NHS resource needed to find each new lung cancer case.
Additionally the company has been notified that The National Institute for Health and Care Excellence (NICE) has selected the EarlyCDT Lung blood test for Diagnostics Assessment Guidance.
Oncimmune Holdings plc was referenced in the following research papers
Feb 25 2021 Read 207 Times
In This Edition Articles - Expanding the Boundaries of Light Scattering for Macromolecules - Electrostatic Charges and Their Effects on Weighing - How the world’s most advanced analytical...
View all digital editions
Feb 28 2021 Virtual event
Mar 03 2021 Guanghzou, China
Mar 08 2021 Virtual Event
Mar 22 2021 Digital event
Apr 14 2021 Tokyo, Japan